GlassScriptPhysician profile
David A Mccann
NPI 1588633358
$1,053.71
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.81 · 2020: $19.42 · 2021: $692 · 2022: $215 · 2023: $47.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $149.32 | 2019-2022 | |
| Amgen INC. | $140.27 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $136.75 | 2021 | |
| Dexcom, INC. | $101.30 | 2021-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $98.14 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.69 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $59.13 | 2020-2021 | |
| Esperion Therapeutics, INC. | $51.69 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.41 | 2021-2022 | |
| Abbvie INC. | $37.10 | 2021 | |
| Pfizer INC. | $32.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.44 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.84 | 2022 | |
| Abbott Laboratories | $15.04 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11.77 | 2021 | |
| Shire North American Group INC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mccann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.